Antisense drug developer Genta said this week that it has named Per Lindell as vice president of business development.
In this role, Lindell will have "broad responsibility for expanding the company's worldwide business development activities, including partnering negotiations for the company's lead anticancer product, Genasense, as well as in-licensing and acquisition of new products and technology," Genta said.
Previously, Lindell was vice president of corporate development at Metaphore Pharmaceuticals. Before that, he was vice president of business development at Avalon Pharmaceuticals. He holds an ScD in biochemical engineering from the Massachusetts Institute of Technology, and an Msc in chemical engineering from the Royal Institute of Technology in Stockholm.
Genta also said this week that it has appointed Lloyd Sanders as vice president of sales and marketing.
Sanders previously served as vice president of oncology sales at Sanofi-Aventis. He holds a BBA from Memphis State University.
Sigma-Aldrich said this week that it has released a new version of its Mission TRC shRNA human and mouse libraries.
According to the company, the libraries now carry about 65,000 shRNA vector constructs targeting 9,500 human genes and 3,400 mouse genes.
The newly added libraries include extensive coverage of the druggable genome and other highly studied targets, Sigma-Aldrich said.